These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15861713)

  • 21. Innate immunity: NKT cells in the spotlight.
    Van Kaer L; Joyce S
    Curr Biol; 2005 Jun; 15(11):R429-31. PubMed ID: 15936267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of alphaGalCer-induced TCRValpha24 Vbeta11(+) natural killer T cells on NK cell cytotoxicity in umbilical cord blood.
    Ueda Y; Hagihara M; Gansuvd B; Yu Y; Masui A; Okamoto A; Higuchi A; Tazume K; Kato S; Hotta T
    Cancer Immunol Immunother; 2003 Oct; 52(10):625-31. PubMed ID: 12802518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased infiltration of CD1d and natural killer T cells in periodontal disease tissues.
    Amanuma R; Nakajima T; Yoshie H; Yamazaki K
    J Periodontal Res; 2006 Feb; 41(1):73-9. PubMed ID: 16409258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homeostasis of V alpha 14i NKT cells.
    Matsuda JL; Gapin L; Sidobre S; Kieper WC; Tan JT; Ceredig R; Surh CD; Kronenberg M
    Nat Immunol; 2002 Oct; 3(10):966-74. PubMed ID: 12244311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The outlook for CD1d-activated dendritic cell immunotherapy].
    Nieda M; Juji T
    Rinsho Ketsueki; 1999 Jun; 40(6):472-5. PubMed ID: 10422281
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
    Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-21-induced Bepsilon cell apoptosis mediated by natural killer T cells suppresses IgE responses.
    Harada M; Magara-Koyanagi K; Watarai H; Nagata Y; Ishii Y; Kojo S; Horiguchi S; Okamoto Y; Nakayama T; Suzuki N; Yeh WC; Akira S; Kitamura H; Ohara O; Seino K; Taniguchi M
    J Exp Med; 2006 Dec; 203(13):2929-37. PubMed ID: 17178921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NKT cells: T lymphocytes with innate effector functions.
    Van Kaer L
    Curr Opin Immunol; 2007 Jun; 19(3):354-64. PubMed ID: 17428648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A role for natural killer T cells and CD1d molecules in counteracting suppression of hematopoiesis in mice induced by infection with murine cytomegalovirus.
    Broxmeyer HE; Dent A; Cooper S; Hangoc G; Wang ZY; Du W; Gervay-Haque J; Sriram V; Renukaradhya GJ; Brutkiewicz RR
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):87-93. PubMed ID: 17379092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoregulation of autoimmunity by natural killer T cells.
    Linsen L; Somers V; Stinissen P
    Hum Immunol; 2005 Dec; 66(12):1193-202. PubMed ID: 16690406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NKT and tolerance.
    Diana J; Beaudoin L; Gautron AS; Lehuen A
    Methods Mol Biol; 2011; 677():193-206. PubMed ID: 20941612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural killer T cells as targets for immunotherapy of autoimmune diseases.
    Van Kaer L
    Immunol Cell Biol; 2004 Jun; 82(3):315-22. PubMed ID: 15186263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion.
    Dhodapkar KM; Cirignano B; Chamian F; Zagzag D; Miller DC; Finlay JL; Steinman RM
    Int J Cancer; 2004 May; 109(6):893-9. PubMed ID: 15027123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.
    Motohashi S; Okamoto Y; Yoshino I; Nakayama T
    Clin Immunol; 2011 Aug; 140(2):167-76. PubMed ID: 21349771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Translational research of NKT cell-based immunotherapy].
    Motohashi S; Nakayama T
    Nihon Yakurigaku Zasshi; 2010 Dec; 136(6):344-7. PubMed ID: 21139286
    [No Abstract]   [Full Text] [Related]  

  • 36. NKT-cell-based immunotherapies in clinical trials.
    Exley MA; Nakayama T
    Clin Immunol; 2011 Aug; 140(2):117-8. PubMed ID: 21592864
    [No Abstract]   [Full Text] [Related]  

  • 37. CD1-restricted T cells and tumor immunity.
    Swann JB; Coquet JM; Smyth MJ; Godfrey DI
    Curr Top Microbiol Immunol; 2007; 314():293-323. PubMed ID: 17593666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell receptors get back to basics.
    Jones EY; Salio M; Cerundolo V
    Nat Immunol; 2007 Oct; 8(10):1033-5. PubMed ID: 17878911
    [No Abstract]   [Full Text] [Related]  

  • 39. [IV.Clinical trial of immunotherapy for lung cancer].
    Takenoyama M; Ichinose Y
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):1018-20. PubMed ID: 24151659
    [No Abstract]   [Full Text] [Related]  

  • 40. Immune privilege: keeping an eye on natural killer T cells.
    Hong S; Van Kaer L
    J Exp Med; 1999 Nov; 190(9):1197-200. PubMed ID: 10544192
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.